This database was last updated in October 2019 and should only be used as a historical snapshot. There may be new information that is not included here.
Brett Giroir
Health and Human Services (joined: Feb. 7, 2018)
Assistant Secretary for Health | Financial Disclosure »
Bio, via White House:
Dr. Giroir currently serves as President and CEO of ViraCyte, LLC and as an Adjunct Professor of Pediatrics, Tropical Medicine and Medical Ethics and Health Policy at Baylor College of Medicine in Houston. Prior to that he was the Executive Vice President and CEO at the Texas A&M Health Science Center, and earlier he served as Director, Defense Science Office of the Defense Advanced Research Projects Agency (DARPA), and also as a Chief Medical Officer at Children’s Health in Dallas, as well as a Professor at the University of Texas Southwestern Medical Center. He earned a A.B., magna cum laude in Biology from Harvard University and his M.D. from the University of Texas Southwestern Medical Center. He has received the Secretary of Defense Medal for Outstanding Public Service and the Texas A&M University System Award for Innovation. He serves as Chair of the Veterans Choice Act Blue Ribbon Panel to Review and Assess the Veterans Health System, a Scientific Advisory Board Member at the Cancer Moonshots Program, MD Anderson Cancer Center, and is a Scientific Advisory Board Member at the A. Alfred Taubman Medical Research Institute, University of Michigan.
Former Positions Outside Government
- Baylor College of Medicine Adjunct Professor
- BioHouston Board Member
- BrainCheck, Inc. Scientific Advisory Board
- Esperance Pharmaceuticals, Inc. Board Member
- Health Science and Biosecurity Partners, LLC CEO (This entity is sole proprietorship and the vehicle for consulting activities of Dr. Giroir.)
- NonInvasix, Inc. Scientific Advisory Board
- Texas A&M University Health Science Center Executive VP and CEO (Also Professor in Colleges of Medicine and Engineering.)
- University of Michigan A. Alfred Taubman Medical Research Institute Scientific Advisory Board
- University of North Texas Health Science Center Special Assistant to the President (Led development and strategy for UNTHSC Institute for Patient Safety)
- University of Texas MD Anderson Cancer Center Scientific Advisory Board
- ViraCyte, LLC Consultant CEO
Former Compensation Sources
- A. Alfred Taubman Medical Research Institute Through my LLC, served as a member of the scientific advisory board.
- Bellicum Pharmaceuticals Provided consulting services through my LLC on behalf of Pillsbury Winthrop Shaw Pittman LLP.
- BrainCheck, Inc. Served on Scientific Advisory Board
- Esperance Pharmaceuticals Through my LLC, I served as a member of the board of directors, and I also did additional strategic planning as a consultant through Pillsbury Winthrop Shaw Pittman LLP.
- Health Science and Biosecurity Partners, LLC This is my personal, single member LLC. All my consulting and board duties are performed through this LLC
- Intendet Holdings Provided consulting services through my LLC on behalf of Pillsbury Winthrop Shaw Pittman LLP.
- Kirchner Group Through my LLC, served as a consultant for biotechnology and academic enterprise strategy.
- MITRE Corporation MITRE is an FFRDC. Through my LLC, I served as a consultant to Chair the Veterans Choice Act Blue Ribbon Panel as part of MITRE's contract for this assessment.
- NonInvasix, Inc. Served on Scientific Advisory Board
- Pillsbury Winthrop Shaw Pittman LLP Through my LLC, I served as a scientific and technical consultant to biotech start-ups receiving legal services from Pillsbury.
- Texas A&M University Health Science Center Served as Executive VP and CEO. Provided leadership for 5 Colleges, faculty health care providers, and staff.
- Texas Medical Center Through my LLC, served as a consultant advisor to the TMC Health Policy Institute and the TMC Innovation Institute.
- University of North Texas Health Science Center Served as Special Assistant to the President to lead the development and initial implementation of a State of Texas Funded Patient Safety Institute.
- ViraCyte, LLC Through my LLC, I served as a consultant CEO planning strategy, clinical trials, and fund raising.
Employment Assets
| Description | Value | Income |
|---|---|---|
| Texas A&M University Health Science Center | $118,846 | |
| University of North Texas Health Science Center | $88,412 | |
| Traditional IRA | ||
| Fidelity Government Cash Reserves (FDRXX) | $250,001 - $500,000 | None (or less than $201) |
| Fidelity International Small Cap Fund (FISMX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity China Region Fund (FHKCX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity Diversified International Fund (FDIVX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity International Capital Appreciation Fund (FIVFX) | $1,001 - $15,000 | None (or less than $201) |
| Fidelity Small Cap Discovery Fund (FSCRX) | $50,001 - $100,000 | None (or less than $201) |
| Fidelity Europe Fund (FIEUX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity Low Priced Stock Fund (FLPSX) | $50,001 - $100,000 | None (or less than $201) |
| Fidelity Real Estate Income Fund (FRIFX) | $50,001 - $100,000 | None (or less than $201) |
| Fidelity Leveraged Company Stock Fund (FLVCX) | None (or less than $1,001) | None (or less than $201) |
| Fidelity Select Energy Portfolio (FSENX) | $50,001 - $100,000 | None (or less than $201) |
| Fidelity Select Health Care Portfolio (FSPHX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity Select Financial Services Portfolio (FIDSX) | $1,001 - $15,000 | None (or less than $201) |
| Fidelity Select Banking Portfolio (FSRBX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity Select Biotechnology Portfolio (FBIOX) | $50,001 - $100,000 | None (or less than $201) |
| FMI International Fund (FMIJX) | $15,001 - $50,000 | None (or less than $201) |
| Oakmark International Investor Class Fund (OAKIX) | $1,001 - $15,000 | None (or less than $201) |
| Oakmark Equity & Income Investor Class Fund (OAKBX) | $1,001 - $15,000 | None (or less than $201) |
| Permanent Portfolio Class I (PRPFX) | $15,001 - $50,000 | None (or less than $201) |
| T Rowe Price European Stock Fund (PRESX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity New Markets Income Fund (FNMIX) | $50,001 - $100,000 | None (or less than $201) |
| Fidelity Capital & Income Fund (FAGIX) | $100,001 - $250,000 | None (or less than $201) |
| Fidelity Total Bond Fund (FTBFX) | $50,001 - $100,000 | None (or less than $201) |
| Fidelity Strategic Income Fund (FSICX) | $100,001 - $250,000 | None (or less than $201) |
| Double Line Total Return Bond Fund (DLTNX) | $50,001 - $100,000 | None (or less than $201) |
| PIMCO Total Return Class D Fund (PTTDX) | $50,001 - $100,000 | None (or less than $201) |
| PIMCO Income Fund Class D Fund (PONDX) | $50,001 - $100,000 | None (or less than $201) |
| TCW Total Return Bond Class N Fund (TGMNX) | $15,001 - $50,000 | None (or less than $201) |
| SPDR Gold Shares (GLD) | $15,001 - $50,000 | None (or less than $201) |
| Apple Inc (AAPL) | $15,001 - $50,000 | None (or less than $201) |
| Bellicum Pharmaceuticals Inc (BLCM) | $15,001 - $50,000 | None (or less than $201) |
| Cognizant Technology Solution Corp (CTSH) | $50,001 - $100,000 | None (or less than $201) |
| Essa Pharma Inc (EPIX) | $1,001 - $15,000 | None (or less than $201) |
| Facebook (FB) | $15,001 - $50,000 | None (or less than $201) |
| Soligenix Inc (SNGX) | $1,001 - $15,000 | None (or less than $201) |
| Southwest Airlines Co (LUV) | $15,001 - $50,000 | None (or less than $201) |
| SEP IRA | ||
| US Brokerage Account (Cash Account) | $50,001 - $100,000 | None (or less than $201) |
| Fidelity Balanced Fund (FBALX) | $1,001 - $15,000 | None (or less than $201) |
| Fidelity Low Priced Stock Fund (FLPSX) | $1,001 - $15,000 | None (or less than $201) |
| Fidelity Strategic Income Fund (FSICX) | $15,001 - $50,000 | None (or less than $201) |
| Health Science and Biosecurity Partners, LLC (independent consulting business) | None (or less than $1,001) | $424,144 |
| "Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardinal depressant factor," Patent #8,747,843 (value not readily ascertainable) | None (or less than $201) | |
| "Macrophage migration inhibitory factor as a marker for cardiovascular risk," Patent #7,445,886 (value not readily ascertainable) | $1,001 - $2,500 | |
| Esperance Pharmaceuticals Inc. vested Stock Options | $15,001 - $50,000 | None (or less than $201) |
| Esperance Pharmaceuticals Inc. Stock Options: 25,000 unvested shares, strike $0.34, vest 2/26/2018, exp. 2/26/2028 (value not readily ascertainable) | None (or less than $201) | |
| BrainCheck, Inc. vested Stock Options | $1,001 - $15,000 | None (or less than $201) |
| BrainCheck, Inc., Stock Options (value not readily ascertainable): 16,620 unvested shares, strike $0.04, vest 638 shares per month, exp. 10/30/2026 | None (or less than $201) | |
| NonInvasix, Inc. Stock Options (value not readily ascertainable): 21,399 vested shares, strike $1.08, exp. 2027 | None (or less than $201) | |
| NonInvasix, Inc. Stock Options (value not readily ascertainable): 21,399 unvested shares, strike $1.08, vest 1783 shares per month, exp. 2027 | None (or less than $201) | |
| ViraCyte, LLC (Biotech Start Up for Treatment of Infectious Diseases) Profits Interest (value not readily ascertainable) | None (or less than $201) |
Other Income/Assets
| Description | Value | Income |
|---|---|---|
| US Brokerage Account | ||
| Fidelity Government Money Market Fund (SPAXX) | $100,001 - $250,000 | None (or less than $201) |
| Fidelity Small Cap Enhanced Index Fund (FCPEX) | $15,001 - $50,000 | None (or less than $201) |
| Fidellity ContraFund (FCNTX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity Europe Fund (FIEUX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity Balanced Fund (FBALX) | $100,001 - $250,000 | None (or less than $201) |
| Fidelity Low Priced Stock Fund (FLPSX) | $50,001 - $100,000 | None (or less than $201) |
| Fidelity OTC Portfolio (FOCPX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity Select Materials Portfolio (FSDPX) | $15,001 - $50,000 | None (or less than $201) |
| Fidelity Intermediate Municipal Income Fund (FLTMX) | $100,001 - $250,000 | None (or less than $201) |
| Fidelity Municipal Money Market Fund (FTEXX) | $100,001 - $250,000 | None (or less than $201) |
| Bellicum Pharmaceuticals Inc (BLCM) | $15,001 - $50,000 | None (or less than $201) |
| NeuStar Inc Class A (NSR) | $1,001 - $15,000 | None (or less than $201) |
| Oasis Petroleum Inc Com (OAS) | $15,001 - $50,000 | None (or less than $201) |
| Whole Foods Market Inc (WFM) | $1,001 - $15,000 | None (or less than $201) |
| US Bank Account (Cash Account) (Family checking and savings accounts.) | $100,001 - $250,000 | None (or less than $201) |
| Mass Mutual Variable Life Insurance Policy | ||
| Oppenheimer Global Fund | $1,001 - $15,000 | None (or less than $201) |
| T Rowe Price Mid Cap Growth Portfolio | $1,001 - $15,000 | None (or less than $201) |
| MML Managed Bond Fund | $1,001 - $15,000 | None (or less than $201) |
| MML Equity Index Fund | $15,001 - $50,000 | None (or less than $201) |
| BrainCheck Stock | $15,001 - $50,000 | None (or less than $201) |
Employment Agreements and Arrangements
| Employer or Party | City, State | Status and Terms | Date |
|---|---|---|---|
| BrainCheck, Inc. | Houston, Texas | I will divest my vested stock options. I will forfeit my unvested stock options. | Feb. 15, 2016 |
| Health Science and Biosecurity Partnes, LLC | College Station, Texas | This is my personal single member LLC. It will remain inactive while I am in my HHS position. There will be no outstanding fees when I assume the HHS position. | Dec. 16, 2015 |
| Esperance Pharmaceuticals Inc. | Houston, Texas | I will divest my vested stock options. I will forfeit my unvested stock options. | Feb. 15, 2016 |
| NonInvasix, Inc. | Houston, Texas | I will divest my vested stock options. I will forfeit my unvested stock options. | Oct. 16, 2016 |
| ViraCyte, LLC | New Brighton, Minnesota | I will divest my vested profits interest in the company. I will forfeit my unvested profits interest in the company. | Oct. 16, 2016 |
Spouse's Employment Assets
| Description | Value | Income Type | Income Amount |
|---|---|---|---|
| Traditional IRA (This was a lump sum distribution. I have no continuing retirement plan with Texas A&M University.) | |||
| Fidelity Government Cash Reserves (FDRXX) | None (or less than $1,001) | None (or less than $201) | |
| Fidelity Diversified International Fund (FDIVX) | $1,001 - $15,000 | None (or less than $201) | |
| Fidelity ContraFund (FCNTX) | $1,001 - $15,000 | None (or less than $201) | |
| Fidelity Puritan Fund (FPURX) | $1,001 - $15,000 | None (or less than $201) | |
| Roth IRA | |||
| Fidelity Diversified International Fund (FDIVX) | $1,001 - $15,000 | None (or less than $201) | |
| Fidelity Contrafund (FCNTX) | $1,001 - $15,000 | None (or less than $201) | |
| Fidelity Puritan Fund (FPURX) | $1,001 - $15,000 | None (or less than $201) |
Do you know something about Brett Giroir? Send us an email at [email protected] or send a Signal message to 347-244-2134.
See more staffers at Health and Human Services »